ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Mylan lands biosimilar sucker punch to Amgen’s blockbuster
pharmafile
June 07, 2018Mylan and Biocon have received FDA approval for their biosimilar to Amgen’s Neulasta (pegfilgrastim), setting the companies on track to snatch a chunk of the treatment’s $4.2 billion per year in sales, as recorded last year.
Pharma Sources Insight July 2025
